This partially can be explained by the fact that pre-therapeutically induced anemia (Hb < 10 g/dl) and thrombocytopenia (platelet counts < 150 G/L) progressed during 223Ra treatment. This evidence concerns the gene GSTM1 and Thrombocytopenia.